Atlas Trials

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Clinical trial NCT04532294 · COMPLETED

Trial details

NCT number
NCT04532294
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Covid19
Start date
2020-09-08
Primary completion
2021-02-13
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.